drugset / Trial / NCT00961038

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00961038

Phase 1 Completed 19 enrolled Bayer Novartis Pharmaceuticals · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to GOLD Criteria)

Timeline

Start
2009-08
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 50 mg Inhaled
Subject Ciprofloxacin Small molecule 75 mg Inhaled